Sung Lillian, Robinson Paula, Treister Nathaniel, Baggott Tina, Gibson Paul, Tissing Wim, Wiernikowski John, Brinklow Jennifer, Dupuis L Lee
Division of Haematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Pediatric Oncology Group of Ontario, Toronto, Ontario, Canada.
BMJ Support Palliat Care. 2017 Mar;7(1):7-16. doi: 10.1136/bmjspcare-2014-000804. Epub 2015 Mar 27.
To develop an evidence-based clinical practice guideline for the prevention of oral mucositis in children (0-18 years) receiving treatment for cancer or undergoing haematopoietic stem cell transplantation (HSCT).
The Mucositis Prevention Guideline Development Group was interdisciplinary and included internationally recognised experts in paediatric mucositis. For the evidence review, we included randomised controlled trials (RCTs) conducted in either children or adults evaluating the following interventions selected according to prespecified criteria: cryotherapy, low level light therapy (LLLT) and keratinocyte growth factor (KGF). We also examined RCTs of any intervention conducted in children. For all systematic reviews, we synthesised the occurrence of severe oral mucositis. The Grades of Recommendation, Assessment, Development and Evaluation approach was used to describe quality of evidence and strength of recommendations.
We suggest cryotherapy or LLLT may be offered to cooperative children receiving chemotherapy or HSCT conditioning with regimens associated with a high rate of mucositis. We also suggest KGF may be offered to children receiving HSCT conditioning with regimens associated with a high rate of severe mucositis. However, KGF use merits caution as there is a lack of efficacy and toxicity data in children, and a lack of long-term follow-up data in paediatric cancers. No other interventions were recommended for oral mucositis prevention in children.
All three specific interventions evaluated in this clinical practice guideline were associated with a weak recommendation for use. There may be important organisational and cost barriers to the adoption of LLLT and KGF. Considerations for implementation and key research gaps are highlighted.
制定一项基于证据的临床实践指南,用于预防接受癌症治疗或进行造血干细胞移植(HSCT)的0至18岁儿童的口腔黏膜炎。
口腔黏膜炎预防指南制定小组是跨学科的,包括国际公认的儿科黏膜炎专家。对于证据审查,我们纳入了在儿童或成人中进行的随机对照试验(RCT),这些试验评估了根据预先指定标准选择的以下干预措施:冷冻疗法、低强度光疗(LLLT)和角质形成细胞生长因子(KGF)。我们还审查了在儿童中进行的任何干预措施的RCT。对于所有系统评价,我们综合了严重口腔黏膜炎的发生率。采用推荐分级、评估、制定和评价方法来描述证据质量和推荐强度。
我们建议,对于接受化疗或HSCT预处理且治疗方案导致黏膜炎发生率较高的合作儿童,可提供冷冻疗法或LLLT。我们还建议,对于接受HSCT预处理且治疗方案导致严重黏膜炎发生率较高的儿童,可提供KGF。然而,由于儿童缺乏疗效和毒性数据,以及儿童癌症缺乏长期随访数据,使用KGF需谨慎。不推荐使用其他干预措施来预防儿童口腔黏膜炎。
本临床实践指南中评估的所有三种具体干预措施的使用推荐强度均较弱。采用LLLT和KGF可能存在重要的组织和成本障碍。强调了实施方面的考虑因素和关键研究空白。